



Q2 2024 Financial Results

Appendix

Anylam Pharmaceuticals, Inc.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands, except per share amounts)

	Three Months Ended	
	June 30, 2024	June 30, 2023
Reconciliation of GAAP to Non-GAAP Research and development:		
GAAP Research and development	\$ 294,142	\$ 248,526
Less: Stock-based compensation expenses	(48,115)	(32,801)
Non-GAAP Research and development	<u>\$ 246,027</u>	<u>\$ 215,725</u>
Reconciliation of GAAP to Non-GAAP Selling, general and administrative:		
GAAP Selling, general and administrative	\$ 248,397	\$ 214,689
Less: Stock-based compensation expenses	(41,173)	(43,001)
Non-GAAP Selling, general and administrative	<u>\$ 207,224</u>	<u>\$ 171,688</u>
Reconciliation of GAAP to Non-GAAP Operating income (loss):		
GAAP Operating income (loss)	\$ 48,614	\$ (229,831)
Add: Stock-based compensation expenses	89,288	75,802
Non-GAAP Operating income (loss)	<u>\$ 137,902</u>	<u>\$ (154,029)</u>



Anylam Pharmaceuticals, Inc.

Reconciliation of Revenue and Growth at Constant Currency

	Three Months Ended June 30, 2024
Total TTR net product revenue growth, as reported	37 %
Add: Impact of foreign currency translation	2
Total TTR net product revenue growth at constant currency	<u>39 %</u>
Total Rare net product revenue growth, as reported	25 %
Add: Impact of foreign currency translation	1
Total Rare net product revenue growth at constant currency	<u>26 %</u>
Total net product revenue growth, as reported	34 %
Add: Impact of foreign currency translation	1
Total net product revenue growth at constant currency	<u>35 %</u>
Total revenue growth, as reported	107 %
Add: Impact of foreign currency translation	1
Total revenue growth at constant currency	<u>108 %</u>